Posted in | Pharmaceuticals and Drug Discovery | Mass Spectrometry

Advancing hADME with modern AMS tools

From Jul 15 2025

Accelerator Mass Spectrometry (AMS) is having a massive impact on how human ADME studies are conducted, bringing new levels of sensitivity, efficiency, and data quality to pharmacokinetic research.

In this on-demand webinar, leading experts shared the latest AMS-enabled approaches, including the qualification of low-energy AMS (Ionplus LEA) and the integration of CO2-interfaced systems. The session offers practical insights into how these innovations are being applied today and what they mean for the future of drug development.

Key topics covered:

  • Evolving strategies for human ADME studies powered by AMS and where the field is headed
    • Current workflows in ADME execution using AMS and upcoming advancements
  • Qualification of low-energy AMS (Ionplus LEA) and its benefits in sample analysis
    • Integration of CO2-interfaced low-energy AMS and its role in modern ADME research

About the speakers

  • Graeme Young - Consultant at Accelerated Medical Solutions, Ltd.
  • Stephen English - Director, 14C Bioanalysis at Pharmaron
  • Moderator by Marie Croft - Scientific Director, Radiolabeled Sciences at Pharmaron

Other Webinars from Pharmaron

Key considerations for dosimetry from non clinical to clinical application

Key considerations for dosimetry from non clinical to clinical application
Scaling up API production: How to balance speed with supply chain security

Scaling up API production: How to balance speed with supply chain security
The principles of macrocyclic drug discovery

The principles of macrocyclic drug discovery
Smarter drug design with molecular glues

Smarter drug design with molecular glues
Exploring CK1 degrader discovery and molecular glue technologies

Exploring CK1 degrader discovery and molecular glue technologies
Practical in vitro insights into low clearance compounds

Practical in vitro insights into low clearance compounds
Data-driven or physics-based: Choosing the smarter approach to DMPK modeling

Data-driven or physics-based: Choosing the smarter approach to DMPK modeling
What’s changing in DDI guidance? A closer look at ICH M12

What’s changing in DDI guidance? A closer look at ICH M12
Enhancing assay precision for small molecule bioanalysis

Enhancing assay precision for small molecule bioanalysis
Strategies for the successful development of antibody drug conjugates

Strategies for the successful development of antibody drug conjugates
Key ADME and DMPK insights for oligonucleotide drug development

Key ADME and DMPK insights for oligonucleotide drug development

Life Science Webinars by Subject Matter

Watch the
Webinar

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback